Journals Breast Cancer Research and Tre...

Breast Cancer Research and Treatment
Ayako Bun, Masayuki Nagahashi, Mamiko Kuroiwa, Miki Komatsu, Yasuo Miyoshi
PURPOSE: Eribulin is a unique anti-cancer drug which can improve overall survival (OS) of patients with metastatic breast cancer (MBC), probably by modulating the tumor immune microenvironment. The aim of this study was to investigate the clinical significance of serum levels of immune-related and inflammatory cytokines in patients treated with eribulin. Furthermore, we investigated the association between cytokines and immune cells, such as myeloid-derived suppressor cells (MDSCs) and cytotoxic and regulatory T cells, to explore how these cytokines might affect the immune microenvironment...
September 21, 2023: Breast Cancer Research and Treatment
Ana Heredia, Benjamín Walbaum, María Vidal, Laura Itriago, Mauricio Camus, Francisco Dominguez, Manuel Manzor, Raúl Martínez, Geraldine Murature, Sabrina Muñiz, Marisel Navarro, Constanza Guerra, Tomas Merino, Lidia Medina, Carolina Ibañez, Karol Ramirez, Francisco Acevedo, César Sánchez
PURPOSE: The incidence of breast cancer in young women (BCYW) has increased in recent decades. Malignant disease in this subset is characterized by its aggressiveness and poor prognosis. Ovarian function suppression (OFS) in these patients improves survival especially in hormone receptor-positive (HR +) cases. The Regan Composite Risk (RCR) is a prognostic tool to identify high-risk HR + BC candidates for OFS. Our study sought to characterize a Chilean cohort of early HR + BCYW assessing the use of OFS and its related prognosis and the utility of RCR in our patients...
September 21, 2023: Breast Cancer Research and Treatment
Tadafumi Shimizu, Takaaki Oba, Masanori Oshi, Ken-Ichi Ito
PURPOSE: Chemotherapeutic agents exert immunomodulatory effects on triple-negative breast cancer (TNBC) cells and immune cells. Eribulin favorably affects the immunological status of patients with breast cancer. However, the effects of eribulin on the immune cells remain unexplored. The aim of this study was to investigate the effects of eribulin on immune cells. METHODS: Peripheral blood mononuclear cells (PBMCs) from healthy donors and mouse splenocytes were stimulated with anti-CD3 and anti-CD28 antibodies...
September 21, 2023: Breast Cancer Research and Treatment
Yumiko Ishizuka, Yoshiya Horimoto, Hidetaka Eguchi, Fumi Murakami, Katsuya Nakai, Hiroko Onagi, Takuo Hayashi, Takashi Ishikawa, Masami Arai, Junichiro Watanabe
PURPOSE: Breast cancer often metastasizes to the central nervous system. Although the prognosis of brain metastases from breast cancer has been considered poor, and systemic therapy has not contributed to an improved prognosis, newer agents are expected to be more effective. BRCAness is defined as the status of homologous recombination deficiency (HRD) in tumor tissue, regardless of the presence of pathogenic germline BRCA1/2 variants. A study employing next-generation sequencing analysis showed that HRD was found relatively frequently in brain metastases of breast cancer patients...
September 20, 2023: Breast Cancer Research and Treatment
Rowan T Chlebowski, Aaron K Aragaki
PURPOSE: Over the past half century, the annual age-adjusted breast cancer incidence in the USA has fluctuated, potentially influenced by changes in mammography screening, obesity, and menopausal hormone therapy. As the relative contributions of these factors on breast cancer incidence have not been resolved, we assembled reliable sources of year-to-year changes in mammography, obesity, and hormone therapy to graphically display their relationship to breast cancer incidence through 50 years...
September 20, 2023: Breast Cancer Research and Treatment
Nivruthi Shekar, Paton Vuong, Parwinder Kaur
PURPOSE: This research focused on the identification of herbal compounds as potential anti-cancer drugs, especially for breast cancer, that involved the recognition of Notch downstream targets NOTCH proteins (1-4) specifically expressed in breast tumours as biomarkers for prognosis, along with P53 tumour antigens, that were used as comparisons to check the sensitivity of the herbal bio-compounds. METHODS: After investigating phytochemical candidates, we employed an approach for computer-aided drug design and analysis to find strong breast cancer inhibitors...
September 20, 2023: Breast Cancer Research and Treatment
Lise M van Wijk, Sylvia Vermeulen, Natalja T Ter Haar, Claire J H Kramer, Diantha Terlouw, Harry Vrieling, Danielle Cohen, Maaike P G Vreeswijk
PURPOSE: BRCA-deficient breast cancers (BC) are highly sensitive to platinum-based chemotherapy and PARP inhibitors due to their deficiency in the homologous recombination (HR) pathway. However, HR deficiency (HRD) extends beyond BRCA-associated BC, highlighting the need for a sensitive method to enrich for HRD tumors in an alternative way. A promising approach is the use of functional HRD tests which evaluate the HR capability of tumor cells by measuring RAD51 protein accumulation at DNA damage sites...
September 19, 2023: Breast Cancer Research and Treatment
Rajesh Sharma
BACKGROUND AND AIM: Breast cancer (BC) is one of the leading causes of cancer deaths in females in South America. This study aims to examine the BC burden in 12 South American countries between 1990 and 2019. DATA AND METHODS: The estimates of BC burden and risk factors were procured from the Global Burden of Disease 2019 study for the period 1990-2019. Development levels of countries were gauged using socio-demographic index (SDI). Decomposition analysis was employed to categorize the change in incidence between 1990 and 2019 into three factors: population growth, population aging and age-specific incidence rate...
September 17, 2023: Breast Cancer Research and Treatment
Karel Kostev, Matthias Kalder
No abstract text is available yet for this article.
September 15, 2023: Breast Cancer Research and Treatment
Beatriz Costeira, Francisca Brito da Silva, Filipa Fonseca, Rodrigo Oom, Cristina Costa, João Vargas Moniz, Nuno Abecasis, Catarina Rodrigues Santos
BACKGROUND/PURPOSE: Locoregional control in breast cancer is a fundamental part of treatment and determinant for survival outcomes. It has been reported that most locoregional recurrence (LRR) events occur in the first 5 years after treatment. However, LRR continue to occur after this timeline, with unclear risk factors and unknown survival impact. METHODS: Retrospective singe-centered cohort of patients treated for primary breast cancer, between January 2002 and December 2004...
September 14, 2023: Breast Cancer Research and Treatment
Michael A Weintraub, Dazhi Liu, Raymond DeMatteo, Marcus DaSilva Goncalves, James H Flory
PURPOSE: Phosphoinositide 3-kinase (PI3K) inhibition is used for the treatment of certain cancers, but can cause profound hyperglycemia and insulin resistance, for which sodium-glucose cotransporter-2 (SGLT2) inhibitors have been proposed as a preferred therapy. The objective of this research is to assess the effectiveness and safety of SGLT2 inhibitors for hyperglycemia in PI3K inhibition. METHODS: We conducted a single-center retrospective review of adults initiating the PI3K inhibitor alpelisib...
September 13, 2023: Breast Cancer Research and Treatment
Tracy Onega, Linn Abraham, Diana L Miglioretti, Christoph I Lee, Louise M Henderson, Karla Kerlikowske, Anna N A Tosteson, Donald Weaver, Brian L Sprague, Erin J Aiello Bowles, Roberta M di Florio-Alexander
PURPOSE: Invasive lobular carcinoma (ILC) is a distinct histological subtype of breast cancer that can make early detection with mammography challenging. We compared imaging performance of digital breast tomosynthesis (DBT) to digital mammography (DM) for diagnoses of ILC, invasive ductal carcinoma (IDC), and invasive mixed carcinoma (IMC) in a screening population. METHODS: We included screening exams (DM; n = 1,715,249 or DBT; n = 414,793) from 2011 to 2018 among 839,801 women in the Breast Cancer Surveillance Consortium...
September 11, 2023: Breast Cancer Research and Treatment
Xuemiao Zhang, Linfei Huang, Jing Sun, Jialong Liu, Yulong Zong, Luming Wan, Xiaopan Yang, Xue Yan, Yanhong Zhang, Ruzhou Zhao, Jing Liu, Hui Zhong, Congwen Wei, Xiaoli Yang, Yanhong Tai, Yue Han, Yanhai Wang
PURPOSE: The overexpression of mitotic kinase monopolar spindle 1 (Mps1) has been identified in many tumor types, and targeting Mps1 for tumor therapy has shown great promise in multiple preclinical cancer models. However, the role played by Mps1 in tamoxifen (TAM) resistance in breast cancer has never been reported. METHODS: The sensitivity of breast cancer cells to tamoxifen was analysed in colony formation assays and wound healing assays. Enhanced transactivational activity of estrogen receptor α (ERα) led by Mps1 overexpression was determined by luciferase assays...
September 11, 2023: Breast Cancer Research and Treatment
Rebecca Pedersini, Marta Laganà, Sara Bosio, Barbara Zanini, Deborah Cosentini, Pierluigi di Mauro, Andrea Alberti, Greta Schivardi, Lara Laini, Giuseppe Ippolito, Vito Amoroso, Lucia Vassalli, Edda Lucia Simoncini, Alfredo Berruti, Francesco Donato
PURPOSE: We aimed to investigate the role of a lifestyle intervention and clinical and therapeutic factors for preventing weight gain in early breast cancer (BC) patients from one week before to 12 months after chemotherapy. METHODS: Dietary assessments were conducted by a trained dietician using a food-frequency questionnaire at each clinical assessment. Total energy, macronutrients intakes, and physical activity were estimated and the Mediterranean Diet Score (MDS) for adherence to Mediterranean diet was calculated...
September 11, 2023: Breast Cancer Research and Treatment
Ivan Stigliano, Lydia Puricelli, Jorge Filmus, Mari Cleide Sogayar, Elisa Bal de Kier Joffe, Marı A Giselle Peters
No abstract text is available yet for this article.
September 9, 2023: Breast Cancer Research and Treatment
Gulisa Turashvili, Sandra Gjorgova Gjeorgjievski, Qun Wang, Abdulwahab Ewaz, Di Ai, Xiaoxian Li, Sunil S Badve
PURPOSE: Although axillary dissection is no longer indicated for many breast cancer patients with 1-2 positive axillary sentinel lymph nodes (ASLN), intraoperative ASLN assessment is still performed in many institutions for patients undergoing mastectomy or neoadjuvant therapy. With recent advancements in digital pathology, pathologists increasingly evaluate ASLN via remote telepathology. We aimed to compare the performance characteristics of remote telepathology and conventional on-site intraoperative ASLN assessment...
September 9, 2023: Breast Cancer Research and Treatment
Sahil D Doshi, David DeStephano, Melissa K Accordino, Elena Elkin, Rohit R Raghunathan, Jason D Wright, Dawn L Hershman
PURPOSE: Elderly women diagnosed with metastatic breast cancer (MBC) are living longer, however their primary care management may be sub-optimal. Influenza results in preventable hospitalizations and deaths. Guidelines recommend the influenza vaccine for those > 65 years and those with cancer but use is unknown. METHODS: A retrospective analysis was conducted using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data. Patients were included if they were diagnosed with MBC from 1/1/2008-12/31/2017 and were ≥ 65 years of age...
September 9, 2023: Breast Cancer Research and Treatment
Shinsuke Sasada, Naoto Kondo, Hiroya Hashimoto, Yuko Takahashi, Kaori Terata, Kumiko Kida, Yasuaki Sagara, Takayuki Ueno, Keisei Anan, Akihiko Suto, Chizuko Kanbayashi, Mina Takahashi, Rikiya Nakamura, Toshiyuki Ishiba, Michiko Tsuneizumi, Seiichiro Nishimura, Yoichi Naito, Fumikata Hara, Tadahiko Shien, Hiroji Iwata
PURPOSE: Mammography screening has increased the detection of subcentimeter breast cancers. The prognosis for estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative T1a/bN0M0 breast cancers is excellent; however, the necessity of adjuvant endocrine therapy (ET) is uncertain. METHODS: We evaluated the effectiveness of adjuvant ET in patients with ER-positive and HER2-negative T1a/bN0M0 breast cancer who underwent surgery from 2008 to 2012...
September 9, 2023: Breast Cancer Research and Treatment
Steffi Hartmann, Maggie Banys-Paluchowski, Elmar Stickeler, Jana de Boniface, Oreste Davide Gentilini, Michalis Kontos, Stephan Seitz, Gabriele Kaltenecker, Fredrik Wärnberg, Linda Holmstrand Zetterlund, Hans-Christian Kolberg, Sarah Fröhlich, Thorsten Kühn
PURPOSE: Currently, various techniques are available to mark and selectively remove initially suspicious axillary lymph nodes (target lymph nodes, TLNs) in breast cancer patients receiving neoadjuvant chemotherapy (NACT). To date, limited data are available on whether the use of magnetic seeds (MS) is suitable for localizing TLNs. This study aimed to investigate the feasibility of MS in patients undergoing target lymph node biopsy (TLNB) or targeted axillary dissection (TAD) after NACT...
September 8, 2023: Breast Cancer Research and Treatment
Nina Pislar, Gorana Gasljevic, Ivica Ratosa, Anja Kovac, Janez Zgajnar, Andraz Perhavec
PURPOSE: To determine whether the absence of post-treatment changes in the negative sentinel lymph nodes (SLN) in the neoadjuvant setting for biopsy-proven cN + disease results in an increased regional recurrence (RR) rate in patients after SLN biopsy (SLNB) only. METHODS: Breast cancer patients with biopsy-proven cN + disease who converted to node-negative disease after neoadjuvant systemic treatment (NAST) and underwent SLNB only were included...
September 7, 2023: Breast Cancer Research and Treatment
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.